Moomoo AI 已提取核心信息
Shattuck Labs, Inc., a clinical-stage biotechnology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on January 24, 2024. The Austin, Texas-based company, incorporated in Delaware, is registering 3,100,823 shares of common stock for resale, which are issuable upon the exercise of pre-funded warrants acquired by the selling stockholders under a securities purchase agreement dated December 21, 2023. The pre-funded warrants have an exercise price of $0.0001 per share. Shattuck Labs will not receive any proceeds from the sale of shares by the selling stockholders, except for the nominal exercise price upon the cash exercise of the warrants, which will be used for general corporate purposes. The shares may be sold by the selling stockholders from...Show More
Shattuck Labs, Inc., a clinical-stage biotechnology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on January 24, 2024. The Austin, Texas-based company, incorporated in Delaware, is registering 3,100,823 shares of common stock for resale, which are issuable upon the exercise of pre-funded warrants acquired by the selling stockholders under a securities purchase agreement dated December 21, 2023. The pre-funded warrants have an exercise price of $0.0001 per share. Shattuck Labs will not receive any proceeds from the sale of shares by the selling stockholders, except for the nominal exercise price upon the cash exercise of the warrants, which will be used for general corporate purposes. The shares may be sold by the selling stockholders from time to time after the registration statement becomes effective, through various methods described in the 'Plan of Distribution' section. Shattuck Labs' common stock is listed on The Nasdaq Global Select Market under the symbol 'STTK'. As of January 23, 2024, the last reported sale price of Shattuck's common stock was $9.52 per share. The registration statement includes details about the selling stockholders, the use of proceeds, risk factors, and legal matters related to the offering.
临床阶段的生物技术公司Shattuck Labs, Inc. 已于2024年1月24日向美国证券交易委员会（SEC）提交了S-3表格注册声明。这家总部位于德克萨斯州奥斯汀的公司在特拉华州注册成立，注册了3,100,823股普通股进行转售，这些普通股可在行使卖方股东根据2023年12月21日的证券购买协议收购的预先注资认股权证后发行。预先注资的认股权证的行使价为每股0.0001美元。Shattuck Labs不会从出售股东出售股票中获得任何收益，但认股权证现金行使时的名义行使价除外，该权证将用于一般公司用途。注册声明生效后，卖出股东可以通过 “分配计划” 部分中描述的各种方法不时出售股票。Shattuck Labs的普通股在纳斯达克全球精选市场上市，股票代码为 “STTK”。截至2024年1月23日，沙特克普通股最新公布的销售价格为每股9.52美元。注册声明包括有关出售股东、所得款项用途、风险因素以及与发行相关的法律事务的详细信息。
临床阶段的生物技术公司Shattuck Labs, Inc. 已于2024年1月24日向美国证券交易委员会（SEC）提交了S-3表格注册声明。这家总部位于德克萨斯州奥斯汀的公司在特拉华州注册成立，注册了3,100,823股普通股进行转售，这些普通股可在行使卖方股东根据2023年12月21日的证券购买协议收购的预先注资认股权证后发行。预先注资的认股权证的行使价为每股0.0001美元。Shattuck Labs不会从出售股东出售股票中获得任何收益，但认股权证现金行使时的名义行使价除外，该权证将用于一般公司用途。注册声明生效后，卖出股东可以通过 “分配计划” 部分中描述的各种方法不时出售股票。Shattuck Labs的普通股在纳斯达克全球精选市场上市，股票代码为 “STTK”。截至2024年1月23日，沙特克普通股最新公布的销售价格为每股9.52美元。注册声明包括有关出售股东、所得款项用途、风险因素以及与发行相关的法律事务的详细信息。
有用
没用